ClinicalTrials.gg
RecruitingNCT05245695Updated Oct 28, 2026

Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)

An observational study in Endometriosis, sponsored by Aspira Women's Health. Recruiting at 10 sites in United States. Open to female participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Aspira Women's Health · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,200
Ages
14 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.

Planned enrollment
7th of 38
1,200 · median 187
Started
2022
with 14 others
Observational
38 of 169
14 open now
Primary completion
2026-11
later than 5 of 47 live
Registered
118th of 169
by date

Among the 169 studies in Endometriosis with a site in United States, this one is the 7th largest by planned enrollment of the 38 observational ones that give a count, is one of 15 that started in 2022, is one of 38 observational ones, reaches primary completion later than 5 of the 47 other live ones, and was the 118th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 14 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Endometriosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test

Read the detailed description

The objective is to confirm the clinical performance (sensitivity and specificity) of EndoCheck when compared to laparoscopic surgical assessment as an "aid in diagnosis" for endometriosis in subjects who present with chronic pelvic pain.

The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively. Secondary endpoints include examining the performance of the test in patients stratified by pain severity and other clinical factors.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • Biomarkers
  • Deep neural network
04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women scheduled for a gynecologic surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to provide written .
  • Participant is a female aged 14 to 50 years old at time of consent.
  • Participant is scheduled to undergo laparotomy or laparoscopy for symptomology consistent with possible endometriosis

Exclusion criteria

Exclusion Criteria:

  • Participant is a female in a pre-menarchal state.
  • Participant is pregnant.
  • Participant has an active .
  • Participant is known to have tested positive for or hepatitis A, B, or C.
  • Participant has an active pelvic infection or other infections for surgery.
  • Participant has participated (±3 months of study enrollment) in a clinical trial where an drug/ device/ procedure was or is planned to be administered.
  • Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.
  • Participant is under 14 years old or over 50 years old
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherObservational study, no intervention

    Observational study, no intervention

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity

    The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively

    Time frame: 24 months

Secondary outcomes

  1. Performance

    Examining the performance of the test in patients stratified by pain severity and other clinical factors.

    Time frame: 24 months

07

Study locations

10 of 10 sites recruiting
  • New Horizons Clinical Trials
    Chandler, Arizona 852224, United States
    Recruiting
    • Saira Flores, MD · Contactsflores@aoafamily.com
    • · Contact(480) 496-2236
    • Monte Swarup · Principal investigator
  • Velvet Clinical Research
    Burbank, California 91506, United States
    Recruiting
  • Reproductive Associates of Delaware (RAD)
    Newark, Delaware 19713, United States
    Recruiting
  • Midtown OBGYN North
    Columbus, Georgia 31909, United States
    Recruiting
  • Advanced Women's Care Center
    Stockbridge, Georgia 30281, United States
    Recruiting
  • Cindy Basinski, MD
    Forest Hill, Indiana 47630, United States
    Recruiting
    • Alicia Sollman · Contactalicia@drbasinski.com · 812-853-3500
    • Cindy Basinski, MD · Principal investigator
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
    Recruiting
    • Samya El Sayed, MD · Contactselsaye4@jh.edu
    • James Segar, Dr · Principal investigator
  • Nezhat Surgery for Gynecology/Oncology
    Valley Stream, New York 11581, United States
    Recruiting
  • Seven Hills Clinical Research
    Cincinnati, Ohio 45242, United States
    Recruiting
  • Womens Health Services of Central Virginia
    Lynchburg, Virginia 24502, United States
    Recruiting
    • Whittney Calohan · Contactwcalohan@whscv.com · 434-485-7059
    • Wade Neiman · Principal investigator
08

References and documents

Publications

  • Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG. 2004 Nov;111(11):1204-12. doi: 10.1111/j.1471-0528.2004.00433.x. No abstract available. PubMed 15521864 ↗
  • Gupta D, Hull ML, Fraser I, Miller L, Bossuyt PM, Johnson N, Nisenblat V. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD012165. doi: 10.1002/14651858.CD012165. PubMed 27094925 ↗
  • Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997 May;67(5):817-21. doi: 10.1016/s0015-0282(97)81391-x. No abstract available. PubMed 9130884 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Nov 2026, 52 months after the start.

Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 52 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2026 → Nov 2026 and completion Jun 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Feb 18, 2022
StartActual
Jul 12, 2022
Primary completionEst.
Nov 30, 2026was Jun 2026
CompletionEst.
Nov 30, 2026was Jun 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Nov 30, 2026
Oct 28, 2026
Study completion
Jun 30, 2026→Nov 30, 2026
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Jun 30, 2026→Nov 30, 2026
    Study completion Jun 30, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05245695
Lead sponsor
Aspira Women's Health
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jul 12, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 28, 2026

Study contacts

Marla Then, CRC
Contact
mthen@aspirawh.com
844-277-4721
Silvana Franco
Contact
sfranco@aspirawh.com
Todd Pappas, PhD
principal investigator · Aspira Women's Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion